Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process Jackson Center, PA May 2, 2023 – Halberd Corporation (OTC-PINK: "HALB”) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of ...